Singapore's biomedical science sector development strategy: Is it sustainable?

Journal of Commercial Biotechnology

Volumn 10, Issue 4, 2004, Pages 352-362

  Lim, Lisa P L ^a   Gregory, Michael J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Biotechnology; Business model; Cluster; Singapore; Strategy

Indexed keywords

ARTICLE; AUTOMATION; BIOENGINEERING; BIOMEDICINE; BIOTECHNOLOGY; COMMERCIAL PHENOMENA; COMPUTER ANALYSIS; CYTOLOGY; DRUG MANUFACTURE; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; GEOGRAPHY; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NANOTECHNOLOGY; PRODUCTIVITY; SINGAPORE;

EID: 3242717865     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3040093     Document Type: Article

References (6)

1. Wess, L. (2002), 'Regional development - from pill to pillow', in 'BioCentury - The Bernstein Report on BioBusiness', BioCentury Publication, San Carlos, CA, pp. 1-8.
2. Asia Today International (2004), 'Singapore's USD8Bn Gamble', February/March (URL: www.asiatoday.com.au; accessed 1st February, 2004).
3. Businessweek Online (2003), 'Little Island, Big Pharma', 17th February (URL: www.businessweek.com; accessed 10th March, 2004).
4. Reiss, T. (2001), 'Success factors for biotechnology: Lessons from Japan, Germany and Great Britain', Int. J. Biotechnol., Vol. 3(1/2), pp. 134-156.
5. Fisken, J. and Rutherford, J. (2001), 'Business models and investment trends in the biotechnology industry in Europe', J. Comm. Biotechnol., Vol. 8(3), pp. 191-199.
6. Pavlou, A. K. (2003), 'Trends in biotherapeutics', J. Comm. Biotechnol., Vol. 9(4), pp. 358-363.